Tenet Healthcare (NYSE:THC) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tenet Healthcare (NYSE:THC) from a hold rating to a buy rating in a research note published on Sunday morning.

A number of other research analysts also recently weighed in on the stock. Royal Bank Of Canada reduced their target price on shares of Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating for the company in a research report on Friday, May 1st. Barclays lifted their price target on shares of Tenet Healthcare from $240.00 to $271.00 and gave the stock an “overweight” rating in a report on Friday. Robert W. Baird decreased their target price on Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, May 5th. UBS Group boosted their target price on Tenet Healthcare from $288.00 to $308.00 and gave the company a “buy” rating in a research note on Friday. Finally, Wells Fargo & Company increased their price target on Tenet Healthcare from $213.00 to $231.00 and gave the stock an “overweight” rating in a research note on Monday, July 13th. Seventeen equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $268.50.

Tenet Healthcare Trading Up 7.8%

Shares of Tenet Healthcare stock opened at $262.36 on Friday. The stock has a fifty day moving average price of $187.59 and a 200-day moving average price of $198.22. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.41 and a quick ratio of 1.35. The firm has a market cap of $22.60 billion, a PE ratio of 10.12, a P/E/G ratio of 1.37 and a beta of 1.27. Tenet Healthcare has a 1 year low of $155.02 and a 1 year high of $262.68.

Tenet Healthcare (NYSE:THC) last posted its quarterly earnings results on Friday, July 24th. The company reported $6.12 earnings per share for the quarter, beating the consensus estimate of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The company had revenue of $6.04 billion during the quarter, compared to analyst estimates of $5.43 billion. During the same quarter in the prior year, the business earned $4.02 earnings per share. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. Equities research analysts anticipate that Tenet Healthcare will post 20.9 EPS for the current year.

Insider Buying and Selling at Tenet Healthcare

In other news, Director J Robert Kerrey sold 5,638 shares of Tenet Healthcare stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $174.52, for a total value of $983,943.76. Following the completion of the transaction, the director directly owned 16,804 shares in the company, valued at approximately $2,932,634.08. The trade was a 25.12% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paola M. Arbour sold 10,878 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $243.90, for a total value of $2,653,144.20. Following the sale, the executive vice president owned 18,413 shares in the company, valued at approximately $4,490,930.70. The trade was a 37.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 23,353 shares of company stock valued at $5,103,217 over the last 90 days. 0.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tenet Healthcare

Hedge funds and other institutional investors have recently modified their holdings of the stock. Triumph Capital Management bought a new position in shares of Tenet Healthcare in the third quarter valued at approximately $25,000. Activest Wealth Management purchased a new stake in Tenet Healthcare in the 4th quarter worth approximately $26,000. Elyxium Wealth LLC bought a new position in Tenet Healthcare in the 4th quarter valued at $29,000. Meeder Asset Management Inc. grew its position in shares of Tenet Healthcare by 146.2% during the 4th quarter. Meeder Asset Management Inc. now owns 192 shares of the company’s stock valued at $38,000 after purchasing an additional 114 shares in the last quarter. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Tenet Healthcare in the second quarter worth $35,000. 95.44% of the stock is currently owned by institutional investors.

More Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Strong Q2 results and improved outlook: Tenet beat analyst expectations for both earnings and revenue, while raising its 2026 forecast. Performance was driven by solid same-facility growth and disciplined expense management, reinforcing the company’s operating momentum. Tenet Healthcare Tops Q2 Earnings Estimates, Raises 2026 Outlook
• Positive Sentiment: Analysts raise price targets: Truist increased its target to $290 from $270 and maintained a “buy” rating. Guggenheim raised its target to $283 from $242 and also rated the shares “buy.” The upgrades suggest analysts see further upside following the earnings beat and improved guidance. Analyst price-target updates
• Positive Sentiment: Growth-stock appeal: Zacks highlighted Tenet as a highly ranked growth stock, which could attract additional interest from growth, value and momentum-focused investors. Tenet Healthcare Is a Top-Ranked Growth Stock
• Neutral Sentiment: Mixed analyst signal: Robert W. Baird lifted its target sharply to $280 from $210 but retained a “neutral” rating, indicating improved valuation expectations without a full shift to a bullish stance. Analyst price-target update
• Negative Sentiment: Executive and director stock sales: EVP Paola M. Arbour sold 10,878 shares worth approximately $2.65 million, reducing her position by 37.14%. Director Christopher S. Lynch sold 3,837 shares worth about $934,000, cutting his ownership by 28.62%. Although these sales may be for personal or tax-related reasons, the sizable transactions could create a modest overhang for THC. Tenet Healthcare insider transaction filing

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.